Clozapine N-Oxide Administration Produces Behavioral Effects in Long-Evans Rats: Implications for Designing DREADD Experiments

eNeuro. 2016 Nov 1;3(5):ENEURO.0219-16.2016. doi: 10.1523/ENEURO.0219-16.2016. eCollection Sep-Oct 2016.

Abstract

Clozapine N-oxide (CNO) is a ligand for a powerful chemogenetic system that can selectively inhibit or activate neurons; the so-called Designer Receptors Exclusively Activated by Designer Drugs (DREADD) system. This system consists of synthetic G-protein-coupled receptors, which are not believed to be activated by any endogenous ligand, but are activated by the otherwise inert CNO. However, it has previously been shown that the administration of CNO in humans and rats leads to detectable levels of the bioactive compounds clozapine and N-desmethylclozapine (N-Des). As a follow-up, experiments were conducted to investigate the effects of CNO in male Long-Evans rats. It was found that 1 mg/kg CNO reduced the acoustic startle reflex but had no effect on prepulse inhibition (PPI; a measure of sensorimotor gating). CNO (2 and 5 mg/kg) had no effect on the disruption to PPI induced by the NMDA antagonist phencyclidine or the muscarinic antagonist scopolamine. In locomotor studies, CNO alone (at 1, 2, and 5 mg/kg) had no effect on spontaneous locomotion, but 5 mg/kg CNO pretreatment significantly attenuated d-amphetamine-induced hyperlocomotion. In line with the behavioral results, fast-scan cyclic voltammetry found that 5 mg/kg CNO significantly attenuated the d-amphetamine-induced increase in evoked dopamine. However, the effects seen after CNO administration cannot be definitively ascribed to CNO because biologically relevant levels of clozapine and N-Des were found in plasma after CNO injection. Our results show that CNO has multiple dose-dependent effects in vivo and is converted to clozapine and N-Des emphasizing the need for a CNO-only DREADD-free control group when designing DREADD-based experiments.

Keywords: CNO; DREADDs; behavior; voltammetry.

MeSH terms

  • Amphetamine / pharmacology
  • Animals
  • Auditory Perception / drug effects
  • Behavior, Animal / drug effects*
  • Central Nervous System Agents / blood
  • Central Nervous System Agents / pharmacology*
  • Clozapine / administration & dosage
  • Clozapine / analogs & derivatives*
  • Clozapine / blood
  • Clozapine / metabolism
  • Clozapine / pharmacology
  • Designer Drugs
  • Dopamine / metabolism
  • Dose-Response Relationship, Drug
  • Male
  • Motor Activity / drug effects
  • Nucleus Accumbens / drug effects
  • Nucleus Accumbens / metabolism
  • Phencyclidine / pharmacology
  • Rats, Long-Evans
  • Receptors, Muscarinic / metabolism
  • Receptors, Neurotransmitter / metabolism
  • Research Design
  • Scopolamine / pharmacology
  • Sensory Gating / drug effects

Substances

  • Central Nervous System Agents
  • Designer Drugs
  • Receptors, Muscarinic
  • Receptors, Neurotransmitter
  • Amphetamine
  • Scopolamine
  • Phencyclidine
  • Clozapine
  • clozapine N-oxide
  • Dopamine